StreetInsider.com News Articles

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'

Tue, 01 Sep 2026 09:00:04 -0400

(Updated - September 1, 2026 9:00 AM EDT)

Piper Sandler analyst Allison M. Bratzel raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $90.00 (from $88.00) while maintaining a Overweight rating.

The analyst commented: "Yuviwel IP Settlement Removes Overhang, Adds Royalty Revenue; Remain OW rated on BMRN and raising PT on today's news of a settlement with ASND (Ascendis, not covered) over Yuviwel, the long-acting CNP analog for achondroplasia that competes with Voxzogo. The settlement resolves global patent disputes, including the ongoing US ITC (International Trade Commission) case, in exchange for 20% royalties on net sales of Yuviwel in the

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'

Tue, 01 Sep 2026 09:00:04 -0400

(Updated - September 1, 2026 9:00 AM EDT)

Piper Sandler analyst Allison M. Bratzel raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $90.00 (from $88.00) while maintaining a Overweight rating.

Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Tue, 01 Sep 2026 06:58:02 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $114.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented: "Overnight, BMRN announced a global settlement with Ascendis (not covered) resolving all pending patent disputes related to Yuviwel (navepegritide), Ascendis' once-weekly CNP for achondroplasia. Under the terms, Ascendis will pay BMRN a royalty of 20% on net sales in the U.S., retroactive to the first commercial sale, and 18% on net sales in the EU, Brazil, and South Korea through May 2030. The settlement includes a license to BMRN's patents covering Yuviwel for all current and potential indications, including achondroplasia

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright

Mon, 31 Aug 2026 11:02:24 -0400

H.C. Wainwright analyst Mitchell Kapoor raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $60.00 (from $59.00) while maintaining a Neutral rating.

Morgan Stanley on BioMarin Pharmaceutical Inc. (BMRN): 'we think the settlement recognizes the value of BioMarin’s pioneering CNP innovation'

Mon, 31 Aug 2026 11:01:49 -0400

Morgan Stanley analyst Sean Laaman reiterated an Overweight rating and $124.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst comments "By resolving the dispute ahead of a final ITC outcome, BioMarin secures economic value now through retroactive and prospective royalties. The settlement resolves every pending proceeding between the two parties and grants Ascendis broad freedom to operate. BioMarin will dismiss the pending Section 337 investigation, and both sides will resolve all claims relating to the asserted IP. The license extends to BioMarin's Yuviwel-related patents across all current and potential indications and also covers use of Yuviwel in combination with

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies

Mon, 31 Aug 2026 11:00:49 -0400

Jefferies analyst Akash Tewari raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $104.00) while maintaining a Buy rating.

The analyst comments "BMRN announced a global settlement w/ ASND for Yuviwel, which A) gives BMRN royalties on Yuviwel net sales through May 2030 of 20% in the US & 18% EU/BR/KR, and B) resolves all pending patent-related proceedings btwn the co's. We think the agreement adds ~$1/sh NPV and more importantly validates BMRN’s CNP IP + adds credibility to mgmt., removes the Vox litigation overhang, and allows BMRN to share in pot'l upside if Yuviwel gains share.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies

Mon, 31 Aug 2026 11:00:49 -0400

Jefferies analyst Akash Tewari raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $104.00) while maintaining a Buy rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James

Mon, 31 Aug 2026 09:32:41 -0400

(Updated - August 31, 2026 9:32 AM EDT)

Raymond James analyst Chris Raymond raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $105.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on BMRN shares following the company’s announcement of a settlement with Ascendis Pharma (covered by Auster) regarding the outstanding legal dispute over CNP analog Yuviwel, a direct competitor to BioMarin’s Voxzogo, which the company alleged violated BioMarin’s patents. Recall, a preliminary ruling was expected in the coming weeks on this matter at the U.S. International Trade Commission (ITC), where we noted that ITC staff

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James

Mon, 31 Aug 2026 09:32:41 -0400

(Updated - August 31, 2026 9:32 AM EDT)

Raymond James analyst Chris Raymond raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $105.00) while maintaining a Outperform rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James

Mon, 31 Aug 2026 09:32:41 -0400

(Updated - August 31, 2026 9:32 AM EDT)

Raymond James analyst Chris Raymond raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $105.00) while maintaining a Outperform rating.

Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)

Mon, 31 Aug 2026 09:22:34 -0400

Stifel analyst Paul Matteis reiterated a Hold rating and $70.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented, "BMRN announced that they've reached an IP settlement with ASND surrounding Yuviwel and BioMarin's CNP patent estate. For context, a settlement here was the expected outcome by investors, but the economics BMRN will receive (18-20% royalty, paid retroactively) are better than anticipated, and a more legitimate hedge against any lost sales from patient switches. The deal includes the US (20% royalty) and various ex-US territories including the EU, South Korea, and Brazil (18% royalty) which captures most of the Achondroplasia

Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'

Wed, 26 Aug 2026 09:22:41 -0400

Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $88.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented: "Remain Bullish After Hosting Management Meetings; Remain OW rated on BMRN shares after hosting virtual investor meetings with management this week, where the discussion reinforced the broader BMRN thesis beyond the Voxzogo competitive overhang that has dominated the investor debate. The Q2 Voxzogo beat/raise, together with the Amicus revenue, synergy, and deleveraging targets, support higher long-term revenue and profit as Galafold and PomOp benefit from BMRN’s global commercial infrastructure and planned cost synergies. The Alesta acquisition, prioritization of

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright

Wed, 19 Aug 2026 06:44:27 -0400

(Updated - August 19, 2026 6:44 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $59.00 (from $60.00) while maintaining a Neutral rating.

The analyst commented: "BioMarin agreed to acquire Alesta for $275M upfront + up to $215M in development and regulatory milestones, with all non-ALE1 assets spun out before close and no Alesta employees transferring. ALE1-101 is an adaptive Phase 1/2a study in healthy adults and adults with hypophosphatasia (HPP) focused on safety, tolerability, PK/PD and dose selection; under the agreement, ALE1-101 does not qualify as a “Phase 2 Trial” for milestone

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright

Wed, 19 Aug 2026 06:44:27 -0400

(Updated - August 19, 2026 6:44 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $59.00 (from $60.00) while maintaining a Neutral rating.

Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Wed, 19 Aug 2026 06:34:30 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $114.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented: "This morning BMRN announced plans to acquire Alesta Therapeutics. Alesta’s lead asset is ALE1, an oral small molecule in development for hypophosphatasia (HPP)- a rare genetic bone disease caused by mutations in the ALPL gene and a $1.7B+ market based on currently approved Strensiq. We're not surprised by the move based on the co’s recent commentary on its 2Q earnings call and at our recent conference, where mgmt reiterated that the top capital allocation priority remains investing in future growth,

BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform

Wed, 19 Aug 2026 05:30:55 -0400

(Updated - August 19, 2026 5:30 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Outperform rating, PT $98.00.

The analyst comments "We initiate coverage of BioMarin Pharmaceutical (BMRN) with an Outperform rating and a $98 target price. BioMarin is a profitable rare-disease company with durable enzyme therapies, Voxzogo, and new Amicus assets. Given shares trade at roughly 0.64x 2026 versus 2.18x for its peers, we believe investors are overplaying potential Voxzogo erosion with new competition. Also, though its M&A effort might not excite, it makes sense as it leverages BioMarin's core competence of

BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform

Wed, 19 Aug 2026 05:30:55 -0400

(Updated - August 19, 2026 5:30 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Outperform rating, PT $98.00.

Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 17

Tue, 18 Aug 2026 08:39:00 -0400

si-local-file:///var/storage/secattach/20260818/26941225.html

Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 17

Tue, 18 Aug 2026 08:39:00 -0400

si-local-file:///var/storage/secattach/20260818/26941225.html

BioMarin to acquire Alesta Therapeutics for $275M upfront